Overall, this work demonstrates the value of large-scale single cell/nucleus studies in patients to establish the cell-type-specific molecular pathology of C9-ALS and C9-FTD, which will be essential for developing targeted disease-modifying therapies. Here, C9 is linked to frontotemporal dementia.